ClinicalTrials.gg
TerminatedNCT06611423Re-PERFUSEUpdated Sep 24, 2025

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

A Phase 1 interventional study of AZD3427 and AZD3427 Placebo in Heart Failure With Reduced Ejection Fraction (HFrEF) and Renal Impairment, sponsored by AstraZeneca. Terminated at 1 site in Sweden. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The Sponsor encountered difficulties in recruiting patients for clinical trial D8330C00004 and decided to end the study earlier for business reasons not affecting the benefit-risk balance.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
26th of 29
10 · median 24
Started
2024
with 5 others
Phase 1
26 of 29
none open now
Registered
22nd of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 26th largest by enrollment, is one of 6 that started in 2024, is one of 26 in phase 1, and was the 22nd registered.

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 94 Renal Insufficiency studies recruiting now, 49 (52%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).

Read the detailed description

This is a Phase Ib randomised, double-blind, placebo-controlled, single-dose, single-centre study to evaluate the renal haemodynamic effects of AZD3427 in participants with heart failure and reduced eGFR. This study will evaluate changes in the volumetric fraction of perfused renal cortex after a single dose of AZD3427 or AZD3427 placebo. These changes will be assessed using [15O]H2O PET imaging of the kidneys. Additional endpoints include changes in total renal perfusion, plasma/serum biomarkers of renal function, and safety and tolerability. Infusion with 2 to 4 µg/kg/min dopamine/saline placebo will be used as a positive control.

Study details include:

  • The study duration will be up to 83 days.
  • The treatment duration will be 1 day.
  • The visit frequency will be on Day 1, Day 8 (± 3 days), and Day 56 (± 3 days).
03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Renal Impairment

Browse trials for

Keywords

  • Heart failure with reduced ejection fraction
  • HFrEF
  • Renal impairment
  • Reduced eGFR
  • AZD3427
  • PET
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

AGE:

- Participant must be > 20 years-old at the time of signing the .

DISEASE CHARACTERISTICS:

  • Participant must have suitable veins for cannulation.
  • Participants must have a known clinical diagnosis of HF I to III for at least 12 months.
  • Participants must be on stable HF standard of care medication for at least 4 weeks prior to screening, with no significant dose change or new medications added during that period. If the participant is currently taking diuretics, then diuretics must also be stable for at least 4 weeks prior to screening. It is also expected that there will be no change in treatment between screening (Visit 1) and Visit 3 in terms of drugs known to affect renal haemodynamics, including but not limited to: ACE-Is, angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, cyclooxygenase inhibitors, endothelin receptors antagonists, phosphodiesterase inhibitors, SGLT2is, and diuretics.
  • Participants must have a of ≤ 40% based on echocardiography conducted within the last 6 months.
  • Participants must have an of 30 to 90 mL/min/1.73 m2 (inclusive) assessed by the CKD-EPI, 2021 (creatinine only) equation without including race (Inker et al 2021) at screening.

AND WEIGHT:

- Participants must have a minimum BMI of 18.0 kg/m2 and a minimum body weight of 50 kg at screening.

SEX AND REQUIREMENTS:

  • For female participants, the participant must not be pregnant or lactating and must be of non-, confirmed at screening by one of the following:

    1. , defined as amenorrhoea for ≥ 12 months following cessation of all exogenous hormonal treatments, and with FSH levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical sterilisation.
  • All male participants should refrain from fathering a child or donating sperm until 3 months after dosing. The female partner has to be either of non-childbearing potential or has to use a highly effective contraception form of birth control until 3 months after dosing. The female partner should be stable on their chosen method of birth control for at least 3 months prior to dosing.
  • Male participants who have been sterilised are required to use one barrier method of contraception (condom) from the time of study intervention administration until 3 months after the dosing. The participant must have received medical assessment of the surgical success.

INFORMED CONSENT:

- Capable of and willing to give signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

MEDICAL CONDITIONS:

  • History of any disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of screening or planned surgical or other procedure before study completion.
  • Clinically significant, as judged by the investigator, ventricular arrhythmias requiring pharmacological treatment.
  • Historical or current evidence of a clinically significant disease or disorder including, but not limited to:

    1. Myocardial infarction, stroke, , coronary artery bypass grafting, percutaneous coronary intervention, implantable cardioverter defibrillator implantation, within 12 weeks prior to screening.
    2. Primary cardiomyopathy other than dilated, including but not limited to sarcoidosis, amyloidosis, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, complex congenital heart disease.
  • Decompensated HF or hospitalisation due to any cause \< 4 weeks prior to screening.
  • Severe heart valve disease.
  • Diagnosis of polycystic kidney disease or anatomical causes of chronic kidney disease.
  • One kidney, renal artery stenosis, or glomerulonephritis.
  • Anticipated dialysis or renal transplantation within 1 year.
  • Condition where vasodilatory therapy maybe for example but not limited to severe aortic stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy.
  • History of active within 2 years, with the exception of fully excised or treated basal cell carcinoma or ≤ 2 squamous cell carcinomas of the skin.
  • Participants who are under investigation for breast or cervical cancer, including participants with a pap smear of ≥ 3. All investigations must be resolved as negative for breast and cervical cancer at least 12 weeks before screening.
  • Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator.
  • Known or suspected history of drug abuse as judged by the Investigator.
  • History of alcohol abuse or excessive intake of alcohol as judged by the Investigator, within the 6 months prior to screening.
  • History of to injection devices or to drugs with a similar chemical structure or class to AZD3427 or any component of the AZD3427 preparation, or to dopamine or any component of the dopamine preparation, or ongoing clinically important allergy/hypersensitivity.
  • Participants who cannot communicate reliably with the Investigator.
  • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Known history of ADAs to relaxin or relaxin analogues.
  • Active infections that significantly affect the patient's health status or in the opinion of the Investigator, may put the participant at risk (eg, , Hepatitis, tuberculosis, etc.).
  • Plasma donation within 1 month prior to screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.

PRIOR/CONCOMITANT THERAPY:

- If on treatment with other drugs with potential to significantly influence on (eg, SGLT2i, ACE-I), the participant must have been on a stable dose for at least 4 weeks prior to screening.

PDE-5 inhibitors such as sildenafil (eg, taken for erectile dysfunction or other as-needed reasons) and NSAIDs such as diclofenac and ibuprofen should not be taken for 2 days before the PET Sessions 2 and 3 (Visit 2 and Visit 3); paracetamol is allowed.

PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE:

- Currently participating in or previous participation in another clinical study within 30 days prior to the Screening Visit or previous participation in another PET imaging trial within the last 12 months, or planned participation in such study prior to end of the Follow-up period.

Note: Participants consented and screened, but not entered in this study or a previous study, are not excluded.

DIAGNOSTIC ASSESSMENTS:

  • \< 100 g/L at Screening.
  • Abnormal vital signs defined as any of the following at screening:

    1. Sitting SBP > 160 mmHg or sitting DBP > 110 mmHg after a period of at least 5 minutes of rest;
    2. Sitting SBP \< 100 mmHg or sitting DBP \< 50 mmHg;
    3. Resting pulse rate of \< 50 bpm or > 115 bpm.

OTHER EXCLUSIONS:

  • Involvement of any AstraZeneca, CRO, or study centre employee or their close relatives, including any involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Judgement by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the Screening Period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Previous enrolment or randomisation in the present study.
  • For females only: currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    IV Saline placebo followed by SC AZD3427

    Participants will receive IV administration of saline only placebo prior to a PET examination. This is followed by a single SC dose of AZD3427 on Day 1 (V2).

    Biological: AZD3427 · Other: Radiolabelled ligand · Other: Saline

  • Placebo comparator
    IV Saline placebo followed by SC AZD3427 placebo

    Participants will receive IV administration of saline only placebo prior to a PET examination. This is followed by a single SC dose of AZD3427 Placebo on Day 1 (V2).

    Other: AZD3427 Placebo · Other: Radiolabelled ligand · Other: Saline

  • Experimental
    IV Dopamine diluted in saline followed by SC AZD3427

    Participants will receive IV administration of dopamine diluted in saline prior to a PET examination. This is followed by a single SC dose of AZD3427 on Day 1 (V2)

    Biological: AZD3427 · Drug: Dopamine · Other: Radiolabelled ligand

  • Placebo comparator
    IV Dopamine diluted in saline followed by SC AZD3427 placebo

    Participants will receive IV administration of dopamine diluted in saline prior to a PET examination. This is followed by a single SC dose of AZD3427 Placebo on Day 1 (V2).

    Other: AZD3427 Placebo · Drug: Dopamine · Other: Radiolabelled ligand

Interventions

  • BiologicalAZD3427

    AZD3427 SC injection to be prepared using AZD3427 diluent

  • OtherAZD3427 Placebo

    AZD3427 Placebo

  • Dopamine Hydrochloride 50mg/5mL

  • OtherRadiolabelled ligand

    Injection of radioligand for PET examinations

  • OtherSaline

    Saline solution

06

What researchers measure

Primary outcomes

  1. The volumetric fraction (%) of the renal cortex with increased perfusion from baseline to Day 8, compared to placebo.

    A PET image analysis of renal cortex measures the perfusion in approximately 8000 voxels. The volumetric fraction (%) is the fraction of voxels (%) with a positive change, i.e. increased perfusion.

    Time frame: Baseline to Day 8

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Number of participants with adverse events with onset after dose.

    Time frame: Baseline to Day 56

  2. Number of participants with abnormal vital signs

    Predefined criteria for treatment-emergent changes in vital sign parameters will be used.

    Time frame: Baseline to Day 56

  3. Number of participants with abnormal laboratory tests results

    Predefined criteria for treatment-emergent changes in laboratory parameters will be used.

    Time frame: Baseline to Day 56

07

Study locations

1 site
  • Research Site
    Solna, 171 64, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Informed consent form

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Aug 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 25, 2024
StartActual
Oct 15, 2024
Primary completionActual
Aug 21, 2025
CompletionActual
Aug 21, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06611423
Lead sponsor
AstraZeneca
Collaborators
CTC Clinical Trial Consultants AB, Karolinska Institutet
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Oct 15, 2024
Primary completion
Aug 21, 2025
Completion
Aug 21, 2025
Last update
Sep 24, 2025

Study contacts

Kaveh Azizi, MD
principal investigator · Clinical Trial Consultants

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD3427 · Dopamine

Start the discussion